2D-perfusion angiography for intra-procedural endovascular treatment response assessment in chronic mesenteric ischemia: a feasibility study

Annette Thurner*, Anne Marie Augustin, Thorsten Alexander Bley and Ralph Kickuth

Abstract

Background: Endovascular revascularization has become the first-line treatment of chronic mesenteric ischemia (CMI). The qualitative visual analysis of digital subtraction angiography (DSA) is dependent on observer experience and prone to interpretation errors. We evaluate the feasibility of 2D-Perfusion Angiography (2D-PA) for objective, quantitative treatment response assessment in CMI.

Methods: 49 revascularizations in 39 patients with imaging based evidence of mesenteric vascular occlusive disease and clinical signs of CMI were included in this retrospective study. To assess perfusion changes by 2D-PA, DSA-series were post-processed using a dedicated, commercially available software. Regions of interest (ROI) were placed in the pre- and post-stenotic artery segment. In aorto-ostial disease, the inflow ROI was positioned at the mesenteric artery orifice. The ratios outflow to inflow ROI for peak density (PD), time to peak and area-under-the-curve (AUC) were computed and compared pre- and post-interventionally. We graded motion artifacts by means of a four-point scale. Feasibility of 2D-PA and changes of flow parameters were evaluated.

Results: Motion artifacts due to a mobile vessel location beneath the diaphragm or within the mesenteric root, branch vessel superimposition and inadequate contrast enhancement at the inflow ROI during manually conducted DSA-series via selective catheters owing to steep vessel angulation, necessitated exclusion of 26 measurements from quantitative flow evaluation. The feasibility rate was 47%. In 23 technically feasible assessments, PD_{outflow}/PD_{inflow} increased by 65% (p < 0.001) and AUC_{outflow}/AUC_{inflow} increased by 85% (p < 0.001). The time to peak density values in the outflow ROI accelerated only minimally without reaching statistical significance. Age, BMI, target vessel (celiac trunk, SMA or IMA), stenosis location (ostial or truncal), calcification severity, plaque composition or the presence of a complex stenosis did not reach statistical significance in their distribution among the feasible and non-feasible group (p > 0.05).

Conclusions: Compared to other vascular territories and indications, the feasibility of 2D-PA in mesenteric revascularization for CMI was limited. Unfavorable anatomic conditions contributed to a high rate of inconclusive 2D-PA results.

Keywords: 2D-perfusion angiography, Chronic mesenteric ischemia, Endovascular treatment, Mesenteric stenting

Introduction

In chronic mesenteric ischemia (CMI), occlusive disease affecting at least two of three mesenteric arteries causes inadequate blood supply to meet the metabolic demands.
of the intestine [1]. The prevalence of CMI is high in atherosclerotic patients and insidious, often non-specific clinical symptoms hamper timely diagnosis. Patients suffer from ischemic gastro- or enteropathy with malabsorption, usually manifesting as angina abdominalis with postprandial pain, nausea, diarrhea, gastrointestinal bleeding and unintended weight loss [2].

Main goals of revascularization are symptom relief, improvement of the nutritional status and avoiding progression to acute-on-chronic mesenteric ischemia with bowel infarction [1, 3]. Percutaneous, minimally invasive endovascular therapy with stent placement has become the preferred first-line revascularization treatment of CMI [3–9].

During stenting of stenotic mesenteric arteries, the subjective, qualitative visual analysis of monochromatic digital subtraction angiography (DSA) images in the splanchnic territory is challenging. In general, evaluation of disease extent and treatment success in DSA depends on observer experience and is prone to perceptual bias and interpretation errors, leading to a high degree of inter-observer variability and poor reproducibility [10]. Especially in the splanchnic territory, severe aorto-ostial or non-aorto-ostial vessel calcification, vessel tortuosity and angulation may considerably impede procedure planning and visualization of treatment results. In addition, motion artifacts due to breathing or bowel movement with superimposition of bowel gas may substantially limit image interpretation. Furthermore, compared to other vascular regions, radiography of the visceral artery territory requires a larger target volume to be examined and fluoroscopic image quality may be reduced. Therefore, any assistance in procedure planning and treatment success evaluation is welcome.

In different vascular territories and indications, 2D-perfusion angiography (2D-PA) proved to be a useful tool providing on-table visualization of a complete DSA series in a color-coded contrast flow chart as well as objective, intra-procedural quantification of flow changes [11–17]. Nevertheless, 2D-PA in endovascular CMI treatment has not been addressed yet. Therefore, the aim of our study was to evaluate the feasibility of 2D-PA for endovascular treatment assessment in CMI.

Material and methods
Study design and patient characteristics
In total, 49 mesenteric endovascular revascularizations in 39 consecutive patients suffering from CMI were included in this retrospective, single-center observational case–control study. Our study group consisted of 21 men and 18 women with a median age of 69.7 (range 48–87 years), scheduled for endovascular revascularization at our tertiary care hospital from August 2013 to August 2021. At presentation, the leading clinical symptom consisted of recurrent abdominal pain immediately after a meal or, in one case, triggered by hemodialysis-associated hypotension. As a result, the majority of our study population complained unintended weight loss due to food fear and malabsorption. The patients’ weight loss ranged between 7 kg in 48 weeks to 10 kg in 4 weeks. The median BMI was 19.3 kg/m² (range 14.9–34.5). Additionally, 38% of our patients presented with endoscopically proven ischemic gastritis or colitis with intestinal bleeding episodes. The other patients had normal or inconclusive endoscopic results with regard to gastric or colonic ischemic mucosal injury. We present the patients’ demographics and clinical symptoms in Table 1.

Moreover, prerequisite for inclusion was imaging based evidence of occlusive visceral artery disease of atherosclerotic origin in abdominal computed tomographic (CT) or magnetic resonance (MR) imaging. In symptomatic patients, we considered a more than 70% stenosis in single-vessel disease or a more than 50% stenosis in multivessel disease relevant [18]. Preprocedural evaluation of the target visceral arteries with computed tomography revealed moderate (25–50% circumference) to severe (>50% circumference) vessel wall calcification in more than 85% [19]. In computed tomographic imaging, 33% of treated arteries showed calcified plaques, 10% had soft plaques and 57% had a mixed plaque composition. We found triple artery disease, affecting celiac trunk, superior mesenteric artery (SMA) and inferior mesenteric artery (IMA) in 22 patients (including one patient with celiacomesenteric trunk) and double vessel disease in 16 patients. Only one patient had a single vessel disease with a truncal SMA stenosis of more than 70%. In this case, the patient suffered from recurrent severe abdominal pain during hemodialysis, triggered by hemodialysis-associated hypotension. He was on dialysis for five years and had multiple cardiovascular comorbidities (e.g., diabetes mellitus type 2, coronary artery disease with ischemic cardiomyopathy and history of coronary-bypass surgery). Thus, evidence of a diffuse atherosclerotic disease with insufficient collateral flow via the mesenteric arcades induced us to intervene in this particular case. 88% of target arteries had aorto-ostial stenosis. In 22% of our interventions, we found complex visceral artery stenosis with a stenosis length of more than 20 mm and heavily calcified lesions including complete occlusions (maximum stenosis length 40 mm). Compared to DSA, noninvasive imaging had high accuracy in revealing stenoses of >50% or >70%, respectively [20]. We provide an overview of the patients’ visceral artery disease distribution in Table 2.

Our interdisciplinary conference of vascular surgeons and interventional radiologists approved the indication
for endovascular visceral revascularization in each case. In addition, we reviewed clinical and imaging records of each case in our Clinical Information System and Picture Archive and Communication System to collect further information about the patients’ medical history and the post-procedure follow-up of median 21 months (range: 4 months to 7 years).

Procedure technique
One interventional radiologist with 25 years post-certification experience performed the visceral revascularizations via a trans-femoral access route, using a monoplane, ceiling-mounted angiographic system (Axiom Artis Zee, Siemens, Forchheim, Germany). In two cases, catheter instability due to iliac artery elongation and an acute angle between target vessel and aorta necessitated switching to a trans-brachial approach. At least, one stenotic or occluded mesenteric artery had to be recanalized.

The mesenteric target vessels were examined by selective manual angiograms in laterally angled, parasagittal views using different 5 F catheter configurations and iodinated contrast media (Imeron 300; Bracco Imaging, Konstanz, Germany). In order to visualize the extent of aorto-ostial stenosis, a 0.018-inch guidewire was placed through the selective catheter distally to the stenotic segment and a angiogram was performed with the catheter tip being retracted into the aortic lumen next to the mesenteric artery orifice. Intra-arterial contrast was administered manually by a single operator before and after mesenteric revascularization via selective catheters or long guiding sheaths. For separate pre- and

| Table 1 Patients’ demographic and clinical characteristics |
|----------------------------------------------------------|
| Number of patients                                      | 39 |
| Number of procedures                                    | 44 |
| Number of treated arteries                              | 49 |
| **Patients’ demographics**                              |    |
| Median age (years ± standard deviation)                  | 69.7 ± 9.8 |
| Gender (n, %)                                            |    |
| Male                                                     | 21 (54%) |
| Female                                                   | 18 (46%) |
| BMI (kg/m² ± standard deviation)                         | 19.3 ± 10.3 |
| History of (n, %)                                       |    |
| Hypertension                                             | 38 (97%) |
| Heavy smoking (> 20 pack years)                         | 27 (69%) |
| Diabetes                                                 | 21 (53%) |
| Coronary artery disease ± coronary bypass surgery        | 27 (69%) |
| Stroke                                                   | 2 (5%) |
| Peripheral artery disease                               | 28 (72%) |
| Chronic kidney disease stage 1 (GFR > 90 mL/min/1.73m²)  | 7 (18%) |
| Chronic kidney disease stage 2 (GFR 60–89 mL/min/1.73m²) | 13 (33%) |
| Chronic kidney disease stage 3 (GFR 30–59 mL/min/1.73m²) | 12 (31%) |
| Chronic kidney disease stage 4 + 5 (GFR < 29 mL/min/1.73m² or dialysis) | 7 (18%) |
| Anemia (hemoglobin < 13.5 g/dl; hematocrit < 40%)        | 30 (77%) |
| **Clinical characteristics**                            |    |
| Clinical symptoms at presentation (n, %)                 |    |
| Abdominal pain (postprandial)                            | 39 (100%) |
| Weight loss                                              | 36 (92%) |
| Ischemic gastritis/colitis ± bleeding                    | 15 (38%) |
| Immediate post-interventional pain decrease per procedure (n, %) | 42 (95%) |
| Number of patients lost to follow-up after discharge (n, %) | 11 (28%) |
| Weight gain per patient in follow-up (n, %)              | 21 (75%) |
| Recurrence of symptoms per patient in follow-up (n, %)   | 12 (43%) |
| Number of recorded deaths in follow-up (n, %)            | 7 (25%) |
| Bowel-infarction-related death in follow-up (n, %)       | 4 (14%) |

BMI body mass index, GFR glomerular filtration rate
post-interventional hand injection, we used a flow rate of approximately 8 ml/s and a 1:1 normal saline dilution of contrast media (Imeron 300) for each patient regardless of patient size. Only in a few cases, pump-assisted selective angiograms were conducted with 20–30 ml of contrast (80–100% Imeron 300 dilution) and a flow rate of 6–7 ml/s (3 s inject delay, 0 s X-ray delay, 600 psi, injection time 2.9–5 s; Accutron HP-D, Medtron AG, Saarbrücken, Germany). The parameters were chosen

| Table 2 Visceral artery disease, procedure and 2D-PA characteristics |
|---------------------------------------------------------------|
| Number of patients | 39 |
| Number of procedures | 44 |
| Number of treated arteries | 49 |
| **Visceral artery disease characteristics** |
| Visceral artery disease distribution per patient (n, %) | |
| Triple vessel | 22 (56%), incl. 1 celiac-mesenteric trunk |
| Double vessel | 16 (41%) |
| Single vessel | 1 (3%) |
| Stenosis distribution per treated vessel (n, %) | |
| Ostial | 43 (88%) |
| Truncal | 6 (12%) |
| Complex stenosis (stenosis length > 20 mm long, and/or heavily calcified or severely irregular lesions, occlusions) | 11 (22%) |
| Stenosis length (mm) | 5–40 (mm) |
| Target vessel calcification severity per treated vessel (n, %) | |
| Mild (< 25% circumference) | 7 (14%) |
| Moderate (25–50%) | 12 (25%) |
| Severe (> 50% circumference) | 30 (61%) |
| Computed tomographic plaque composition per treated vessel (n, %) | |
| Soft | 5 (10%) |
| Mixed | 28 (57%) |
| Calcified | 16 (33%) |
| **Procedure and 2D-PA characteristics** |
| Revascularization per procedure (n, %) | |
| Single vessel | 40 (91%), incl. 1 celiac-mesenteric trunk |
| Superior mesenteric artery (SMA) | 26 (65%) |
| Celiac Trunk | 11 (28%) |
| Inferior mesenteric artery (IMA) | 3 (7%) |
| Double vessel (SMA + Celiac Trunk) | 3 (7%) |
| Triple vessel (SMA + Celiac Trunk + IMA) | 1 (2%) |
| Stent diameter (mm) / Stent length (mm) | 4–8 (mm) / 12–27 (mm) |
| Bare-metal stenting per treated vessel | 39 (80%) |
| Covered-stenting per treated vessel | 5 (10%) |
| PTA alone per treated vessel | 5 (10%) |
| Technical failure (n, %) | 0 (0%) |
| Major complications per procedure (n, %) | 3 (7%) |
| 2D-PA measurements performed (n, %) | 49 (100%) |
| 2D-PA motion artifact scale per treated artery (n, %) | |
| 1: None | 0 (0%) |
| 2: Mild | 17 (35%) |
| 3: Moderate | 24 (49%) |
| 4: Severe | 8 (16%) |
| Conclusive 2D-PA hemodynamic result (n, %) | 23 (47%) |

2D-PA 2D-perfusion angiography, PTA percutaneous transluminal angioplasty
at the operator's discretion according to the target vessel size and the patients' renal function.

Due to impaired renal function and previously performed diagnostic CT- or MR-angiographic images, we waived pump-assisted aortography in the majority of cases. DSA images were acquired at 2 frames per second with a range of approximately 5–6 s per DSA run.

During the procedure, we did not administer spasmolytic agents.

We assessed major complications according to the reporting standards of the Society of Interventional Radiology [21]. Table 2 includes details of the mesenteric stenting procedure.

Postprocessing and 2D-PA analysis
To evaluate perfusion changes by 2D-PA, we performed post-processing of monochromatic DSA series before and after mesenteric stenting on a dedicated workstation using a commercially available clinical software application (Syngo X Workplace VB20D, Syngo iFlow software, Siemens, Forchheim, Germany). In 2D-PA, a single computed, color-coded composite image provides clustered information about vessel morphology and contrast concentration changes per time during a complete DSA run. In addition, 2D-PA allows calculation of flow curves and blood flow parameters in user-defined regions of interest (ROI). Therefore, 2D-PA enables an objective assessment of flow changes and perfusion parameters.

Initially, we selected pre- and post-interventional DSA series taken in almost identically angled views to be evaluated by 2D-PA. The chosen DSA series were prepared for 2D-PA-analysis by automatic isocenter calibration (calibration factor 0.2017 (mm/Pixel)) according to the instructions for use. Next, in total four ROI were placed, at least one proximally and one distally to the stenotic mesenteric artery segment. ROIs were arranged in the same position pre- and post-interventionally, to ensure measurements at comparable locations. ROIs were adjusted to at least 2/3rd of the vessel diameter. In cases of aorto-ostial disease, we placed the inflow ROI in the aortic lumen next to the mesenteric artery ostium. We located the outflow ROI, intended for statistical analysis, at least 2 cm distally to the stenotic segment. The reported 2D-PA technique using a two ROI based evaluation (a proximal reference ROI and a distal target ROI) is independent of a standardized contrast-bolus protocol [16].

In 2D-PA, the computed time-versus-ROI-contrast-intensity result tables offer the following numeric parameters: ROI Area in mm², the ratio between outflow and inflow maximal contrast density per ROI after contrast media application (ROI Peak/Ref Peak or PD_{outflow}/PD_{inflow}). Furthermore, the time to peak density per ROI in seconds from the first moment of increase of density to the maximum contrast density (ROI Peak time or TTP) and the ratio between outflow and inflow area-under-the-time-density-curve (ROI AUC/Ref AUC or AUC_{outflow}/AUC_{inflow}).

In addition, we calculated the ratio between outflow and inflow time to peak in order to overcome variations in the flow rates between consecutive manual angiograms.

Additionally, we assessed the 2D-PA-images qualitatively for motion artifacts during a DSA run. To this end, we graded motion artifacts by means of a four-point scale (Score 1: artifact-free; Score 2: minimal motion-related artifact with no effect on flow evaluation; Score 3: moderate motion-related artifact with some, but not severe effect on diagnostic quality; Score 4: severe motion-related artifact rendering flow evaluation impossible). Furthermore, we evaluated the time versus contrast density curves with regard to conclusiveness of hemodynamics. We considered results hemodynamically conclusive, if an adequate contrast enhancement is present at the inflow ROI during the DSA run.

In theory, following successful revascularization, the TTP-ratio (TTP_{outflow}/TTP_{inflow}) decreases, since the density peak in the outflow ROI will be reached earlier. The peak density-ratio (PD_{outflow}/PD_{inflow}) increases, since the maximal contrast density in the outflow ROI rises following intervention. Correspondingly, the AUC-ratio (AUC_{outflow}/AUC_{inflow}) increases as well, since the outflow AUC approximates the inflow AUC post-interventionally.

Endpoint definition
We designated technical feasibility as primary endpoint. Technical feasibility was defined as successful completion of the post-processing process, freedom from severe motion artifacts or vessel superimposition and conclusiveness of hemodynamic results. Secondary endpoint for 2D-PA was defined as statistically significant changes of flow parameters pre- and post-interventionally indicating treatment success.

Statistical analysis
Microsoft Excel (Microsoft Office 365 ProPlus, Version 1803) served as a data collection tool. For statistical analysis, we used a dedicated software (R®, Version 4.0.2, The R Foundation for Statistical Computing, Wien, Austria). Descriptive data were presented as means ± standard deviation for normally distributed variables or medians with ranges for non-normally distributed variables. We reported categorical variables as frequencies and percentages with n (%). The Anderson Darling test was applied for assessment of normality, rejecting the hypothesis of normality when the p-value was less or equal to 0.05.
Ratios of peak density, time-to-peak and area under the time-contrast curve pre- and post-interventionally were evaluated for statistical significance by using the pairwise Wilcoxon’s signed rank test for non-normally distributed variables. In addition, we assessed whether parameters, potentially influencing the feasibility, were more frequently represented in the feasible- or non-feasible group by using the fisher’s exact test for nominally scaled variables, the Wilcoxon’s signed rank test for ordinarily scaled variables and the T-test for scaled, normally distributed variables. A p-value of less than 0.05 was designated as statistically significant.

**Results**
Completion of the post-processing process was achieved in each case. With regard to motion artifacts, we recorded mild to moderate artifact levels in 84% of evaluated arteries. In 16% severe motion artifacts rendered adequate flow evaluation impossible. Artifacts were due to a combination of the patients’ inability to hold their breath during a DSA run and bowel movement. In five cases, vessel branching and tortuosity precludes free projection of the intended inflow or outflow vessel segments for ROI placement (Fig. 1). Indeed, in each non-feasible case, insufficient prestenotic contrast enhancement during a manually conducted DSA series via long guiding sheaths or selective catheters was the main reason for impeded 2D-PA assessment (Fig. 2).

As a result, hindered 2D-PA due to motion artifacts, vessel superimposition and inadequate pre-stenotic contrast enhancement necessitated exclusion of overall 26 2D-PA measurements from quantitative flow evaluation. Therefore, the technical feasibility rate of 2D-PA in mesenteric stenting was 47%. Further 2D-PA results are included in Table 2.

Nevertheless, we recorded the following changes of flow parameters pre- and post-interventionally in 23 technically feasible, conclusive 2D-PA measurements: PD and AUC in the target outflow ROI were significantly higher following treatment, resulting in an increase of 65% for PD_{outflow}/PD_{inflow} (p<0.001) and 85% for AUC_{outflow}/AUC_{inflow} (p<0.001). The time to peak density values in the outflow ROI following mesenteric stenting accelerated only minimally without reaching statistical significance (p = 0.553). The decrease in the TTP_{outflow}/ TTP_{inflow} ratio pre- and post-interventionally was -2%. The correlation between the increase of AUC_{outflow}/AUC_{inflow} and the post-procedural weight gain yielded statistical significance (p = 0.016).

Moreover, a subgroup analysis of variables’ impact on the feasibility of 2D-PA yielded no statistical significance in the majority of cases. Age (p = 0.475), BMI (p = 0.343), target vessel (celiac trunk, SMA or IMA; p = 0.234), stenosis location (ostial/truncal; p = 0.086), calcification severity (p = 0.187), plaque composition (p = 0.639) or the presence of a complex stenosis (p = 0.086) did not reach statistical significance in their distribution among the feasible and non-feasible group. A higher artifact level (p = 0.006) and a hemodynamically inconclusive result (p < 0.001) were found more often in the non-feasible group by reaching high statistical significance. Changes in 2D-PA following mesenteric stenting are presented in Table 3, and Fig. 3 offers an example of 2D-PA before and after mesenteric stenting.

**Discussion**
This study adds further aspects to the growing experience in 2D-PA by showing that 2D-PA in the mesenteric territory for treatment evaluation in chronic mesenteric ischemia is challenging. Non-interpretable 2D-PA evaluations necessitated exclusion of 26 measurements from quantitative flow evaluation, resulting in a feasibility rate of 47%. Previously published studies indicated 2D-PA as highly susceptible to motion artifacts, since they cause inaccurate measurements of perfusion parameters. Indeed, in comparison with previously published studies, our feasibility rate was considerably lower. For instance, 2D-PA in peripheral artery disease proved to be technically feasible in all cases reported by Hinrichs et al. and Dewald et al. [16, 17]. Furthermore, Maschke et al. reported no patient exclusion due to hindered 2D-PA assessment in TIPS-revision and an exclusion rate of 13% in 2D-PA assessment following transarterial liver chemoeembolization [13, 14]. In a small patient collective with non-occlusive mesenteric ischemia (NOMI), only 6% of patients had to be excluded due to inadequate 2D-PA analysis [15].

Our results may be triggered by additional challenges in occlusive mesenteric artery disease. First, the mobile vessel location beneath the diaphragm or within the mesenteric root, rendered 2D-PA vulnerable to motion artifacts. Since we did not apply spasmolytic agents during our interventions, their effect on artifact reduction remains unclear. Second, especially in the celiac territory, superimposition of vessel branches precluded free projection of the intended inflow or outflow vessel segments for ROI placement.

However, the main drawback was steep angulation between the aorta and the target vessel. As a result, we recorded insufficient contrast enhancement at the inflow ROI in manually conducted angiograms via selective catheters or long guiding sheaths (Fig. 2). In these cases, 2D-PA flow curves and perfusion measurements were inconclusive. Adequate contrast enhancement at the inflow ROI is one major prerequisite for a reliable application of the reported 2D-PA technique which is based on a two ROI
Fig. 1  Impaired 2D perfusion assessment in a patient with 2-vessel-disease. Preinterventional Volume Rendering CT Angiography image (A), digital subtraction angiogram and 2D perfusion images showing vessel superimposition due to angulation of the celiac trunk (B, D) and blurring of vessel contours due to breathing artifacts in SMA and celiac trunk (C, D)
approach (a proximal reference ROI and a distal target ROI).

Since 49% of our patients had impaired renal function (CKD stages 3 to 5), and previously performed CT- or MR-angiographic images were available in each case, additional aortography solely for 2D-PA reasons was not justified in the majority of our cases. The fact that 2D-PA is independent of additional contrast media application and radiation exposure is one major strength of the reported 2D-PA technique.

Another key feature of the reported 2D-PA technique is “on-table” visualization of color-coded and quantitative flow changes during the procedure. To date, other promising novel imaging techniques enabling flow evaluation and/or color-coding of flow velocities as 4D flow MRI are time consuming and not available intra-procedurally. Further, contrary to 2D-PA, they are prone to artifacts caused by dense calcifications and stent material [22]. In addition, patients with CMI are often diagnosed relatively late in the course of the disease and present with clinically decompensated CMI. Hence, the fragile status of these often multimorbid and elderly patients may hamper the success of elaborate imaging techniques which require additional time and a high level of patient compliance.

In a subgroup analysis, none of the presumed factors influenced the feasibility significantly. Neither a higher patient age, nor a higher BMI were more frequently found in the non-feasible group. Moreover, ostial stenosis as well as the presence of complex stenosis or a higher calcification severity were not significantly differently distributed among the feasible and the non-feasible group. As expected, only a high motion artifact level and an insufficient inflow contrast enhancement proved to be highly significant limitations for 2D-PA.

In accordance with previously published data, 2D-PA evaluation in our feasible group showed a significant increase in the AUC-ratio and the PD-ratio indicating improved perfusion of the treated artery following stenting. In contrast, the TTP-ratio decreased only minimally without reaching statistical significance.

This result is in accordance with Dewald et al., who reported only a low trend towards decrease of the TTP-ratio in their assessment of 2D-PA in CO$_2$-angiography of the limb [17]. The authors attributed the lack of significance to the small sample size in their study (n = 10). Additionally, in our collective, the short distance between the inflow and outflow ROI and the consecutively very short time differences may not be detectable with the 2D-PA technique in a standard DSA run at 2 frames/s. In 2D-PA, density values were assigned to each area within a ROI per DSA run. These density-over-time-values are used to deduce information about flow rates, flow time and maximum values. Hence, in a short distance the flow acceleration may insufficiently be detectable by changes in time to peak density per ROI. In view of the post-stenotic measuring point, Augustin et al. found similar results in their 2D-PA study following stenting for renal artery stenosis.

In their assessment, significant TTP changes were found more distally at the level of the first-order segmental arteries, not in the main renal artery [23]. With the kidneys lying in the retroperitoneal space, 2D-PA measurements in smaller sized, segmental arteries may be less affected by motion artifacts compared to branch vessels within the mesentery. Thus, in our collective, we waived measurements at more distally located vessel branching levels within the mesenteric root, since they were prone to severe motion artifacts. Due to the retrospective design of our study, we were not able to evaluate flow changes more peripherally, e.g. in the portal vein. However, in a study by Becker et al. assessing 2D-PA in NOMI, TTP changes in the portal vein following intervention did not reach statistical significance as well [15].

Furthermore, a combination of the complex vascular anatomy with varying disease distribution patterns, the high capacity of collateral blood circulation, post-prandial flow changes, vessel wall elasticity, the intestinal vascular suction effect as well as post-occlusive reactive vasodilatation complicates the analysis of flow parameters in the mesenteric territory [24]. Previously published Doppler flow evaluations point to the complex compensatory flow changes in this territory. For instance, the IMA potentially serves as a relevant collateral vessel by offering a tenfold flow reserve in chronic SMA/celiac trunk stenosis [25]. In addition, recently published studies point to the fact that visceral flow disturbances impeding reliable flow measurements are an issue in other novel perfusion imaging techniques such as 4D flow MRI as well [26]. Even in healthy visceral arteries the curved and branched anatomy causes disturbed, vortex and/or helical flow, which hampers flow measurements [26]. Especially in combination with ostial visceral artery stenosis, oscillatory and fluctuating time velocity curves have been measured rendering flow evaluation challenging [26].

(See figure on next page.)

**Fig. 2** Preinterventional maximum intensity projection MR-angiography image (A), transfemoral digital subtraction angiogram (B), transbrachial digital subtraction angiogram and 2D perfusion image (C, D) in a patient with filiform ostial stenoses of celiac trunk and SMA. Acute angulation of the celiac trunk to the aorta coupled with transfemoral instability of the catheter system necessitated switching to a transbrachial access route. Insufficient prestenotic aortic contrast enhancement impeded 2D perfusion evaluation via selective catheter angiogram. Due to renal insufficiency, we waived aortography in this case.
Fig. 2 (See legend on previous page.)
Contrary to the creatinine levels in renal artery stenting, we did not consider any clinical or laboratory parameter appropriate for statistical correlation with changes in perfusion parameters to predict the procedures’ outcome in our retrospective data set. Only the correlation between the increase of $\text{AUC}_{\text{outflow}}/\text{AUC}_{\text{inflow}}$ and the post-procedural weight gain yielded statistical significance ($p = 0.016$). However, the clinical relevance of this result is questionable, since the patients’ body weight depends on many factors. Six patients in our feasible group presented with symptom recurrence. Due to the small sample size and a multitude of influencing factors,
correlation between changes in flow parameters and symptom relapse seems not appropriate. This study has several limitations. Due to the retrospective nature of our study, we solely focused on the feasibility of 2D-PA for intra-procedural treatment response assessment during mesenteric stenting and did not perform other techniques such as duplex sonography or pressure wire measurements to compare our 2D-PA results. As previously mentioned, there are many factors influencing the perfusion between the proximal mesenteric artery stenosis and the bowel's capillary system, which are not gathered by the reported 2D-PA technique. Hence, 2D-PA is not able to point to absolute measurements of mesenteric perfusion. Further studies should focus on the influence of the collateral flow and techniques to evaluate the real 3D perfusion of the capillary phase of the mesenteric territories.

The small number of patients, the high number of non-interpretable 2D-PA evaluations and the moderate loss of patients available for follow up in our multi-morbid patient collective rendered a structured follow-up analysis and reliable correlation of 2D-flow parameters with clinical outcome parameters in order to define criteria for effective therapy inadequate.

Conclusions
Compared to other vascular territories and indications, the feasibility of 2D-PA in endovascular mesenteric revascularization for CMI was limited. Unfavorable anatomic conditions contributed to a high rate of inconclusive 2D-PA results. With our data, we intended to contribute to the growing preliminary knowledge about objective treatment assessment with 2D-PA. Especially in the mesenteric territory, further prospective standardized evaluations comparing different flow measurement techniques with larger study populations and structured longitudinal follow up periods are needed to gain deeper insights in the complex mesenteric flow characteristics and to define objective standardized endpoints of successful mesenteric revascularization.

Abbreviations
2D-PA: 2D-perfusion angiography; AUC: Area-under-the-time-density-curve; BMI: Body mass index; CKD: Chronic kidney disease; CMI: Chronic mesenteric ischemia; CT: Computed tomography; DSA: Digital subtraction angiography; IMA: Inferior mesenteric artery; IU: International unit; MR: Magnetic resonance imaging; NOMI: Non-occlusive mesenteric ischemia; PAD: Peripheral artery disease; PD: Peak density; PTA: Percutaneous transluminal angioplasty; ROI: Region of interest; SMA: Superior mesenteric artery; TTP: Time to peak.

Acknowledgements
Not applicable.

Author contributions
Study conception, design and supervision: RK. Data acquisition: RK, AT. Clinical data collection: AT. Clinical data preprocessing: AT, AMA. Literature research: AT. Manuscript preparation: AT. Manuscript editing: AT, AMA, RK, TAB. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This publication was supported by the Open Access Publication Fund of the University of Würzburg.

Availability of data and materials
The data used and analyzed are available on reasonable request. The corresponding author should be contacted if someone wants to request the data.

Declarations
Ethics approval and consent to participate
Before conducting this retrospective study, the ethics committee of the University Hospital Würzburg approved the retrospective study protocol evaluating preexisting clinical and imaging data, which were acquired as part of our clinical routine (Waiver No. 2021061401). The need for informed consent for the study itself was waived due to the retrospective design. All methods performed in this retrospective study were in accordance with appropriate guidelines, including the ethical standards of the University Hospital Würzburg and the 1964 Declaration of Helsinki and its later amendments. The procedures itself were conducted as part of our clinical routine. The patients provided informed, written consent before the procedure according to our clinical standard of care.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 20 November 2021 Accepted: 3 May 2022 Published online: 16 May 2022

References
1. Barnes JA, Columbo JA, Ponukumati AS, Zwolak RM, Olive FT, Goodney PP, Powell RJ, Zacharias N. Long-term outcomes of mesenteric stenting and analysis of in-stent restenosis duplex velocity criteria. Ann Vasc Surg. 2020;68:226–33.
2. Zeller T, Rastan A, Sixt S. Chronic atherosclerotic mesenteric ischemia (CMI). Vasc Med. 2010;15(4):333–8.
3. Blauw J, Bulüt T, Eenhoorn P, Beuk RJ, Brusse-Keizer M, Kolkman JJ. Geelkerken RH. Chronic mesenteric ischemia: when and how to intervene on patients with celiac/SMA stenosis. J Cardiovasc Surg (Torino). 2017;58(2):321–8.
4. Girault A, Pellenc Q, Roussel A, Senemaud J, Cerceau P, Maggiori L, Huguet A, Corcos O, Ben Abdallah I, Castera Y. Midterm results after covered stenting of the superior mesenteric artery. J Vasc Surg. 2021;74(3):902-909.e3.
5. Haben C, Park WM, Bena JF, Parodi FE, Lyden SP. Improving midterm results justify the continued use of bare-metal stents for endovascular therapy for chronic mesenteric ischemia. J Vasc Surg. 2020;71(1):111–20.
6. Scali ST, Ayo D, Giles KA, Gray S, Kubilis P, Back M, Fatima J, Amnaoutakis D, Berceli SA, Beck AW, Uphchurch GJ, Feezor RJ, Huber TS. Outcomes of antegrade and retrograde open mesenteric bypass for acute mesenteric ischemia. J Vasc Surg. 2019;69(1):119–40.
7. Bulüt T, Oosterhof-Berktas R, Geelkerken RH, Brusse-Keizer M, Stassen EJ, Kolkman JJ. Long-term results of endovascular treatment of atherosclerotic stenoses or occlusions of the coeliac and superior mesenteric artery in patients with mesenteric ischaemia. Eur J Vasc Endovasc Surg. 2017;53(4):585–90.
8. Malgor RD, Oderich GS, McKusick MA, Misra S, Kalra M, Duncan AA, Bower TC, Gloviczki P. Results of single- and two-vessel mesenteric artery stents for chronic mesenteric ischemia. Ann Vasc Surg. 2010;24(8):1094–101.
9. Loffroy R, Guiu B, Cercueil JP, Krausé D. Chronic mesenteric ischemia: efficacy and outcome of endovascular surgery. Abdom Imaging. 2010;35(3):306–14.

10. Hoffman C, Penyjasamy S, Longhurst C, Medero R, Roldan-Alzate A, Speidel MA, Laecke PF. A technique for intra-procedural blood velocity quantitation using time-resolved 2D digital subtraction angiography. CVR Endovasc. 2021;4(1):11.

11. Maschke SK, Renne J, Werncke T, Olsson KM, Hoeper MM, Wacker FK, Meyer BC, Hinrichs JB. Chronic thromboembolic pulmonary hypertension: evaluation of 2D-perfusion angiography in patients who undergo balloon pulmonary angioplasty. Eur Radiol. 2017;27(10):4264–70.

12. Maschke SK, Werncke T, Klockner R, Rodt T, Renne J, Kirstein MM, Vogel A, Wacker FK, Meyer BC, Hinrichs JB. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads. Abdom Radiol (NY). 2018;43(5):1245–53.

13. Maschke SK, Werncke T, Renne J, Klockner R, Marquardt S, Kirstein MM, Potthoff A, Wacker FK, Meyer BC, Hinrichs JB. Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction: quantitative assessment of flow and perfusion changes using 2D-perfusion angiography following shunt revision. Abdom Radiol (NY). 2018;43(10):2868–75.

14. Dewald CLA, Meine TC, Winther HMB, Kloeckner R, Maschke SK, Kirstein MM, Vogel A, Wacker FK, Meyer BC, Renne J, Hinrichs JB. Chemo-saturation percutaneous hepatic perfusion (CPH-PH) with melphalan evaluation of 2D-perfusion angiography (2D-PA) for leakage detection of the venous double-balloon catheter. Cardiovasc Intervent Radiol. 2019;42(10):1441–8.

15. Becker LS, Stahl K, Meine TC, von Falck C, Meyer BC, Dewald CLA, Rittgerodt N, Busch M, David S, Wacker F, Hinrichs JB. Non-occlusive mesenteric ischemia (NOMI): evaluation of 2D-perfusion angiography (2D-PA) for early treatment response assessment. Abdom Radiol (NY). 2020;45(10):3342–51.

16. Hinrichs JB, Murray T, Akin M, Lee M, Brehm MU, Wilhelmi M, Wacker FK, Rodt T. Evaluation of a novel 2D perfusion angiography technique independent of pump injections for assessment of interventional treatment of peripheral vascular disease. Int J Cardiovasc Imaging. 2017;33(3):295–301.

17. Dewald CLA, Becker LS, Maschke SK, Meine TC, Meyer BC, Wacker FK, Hinrichs JB. 2D-perfusion angiography using carbon dioxide (CO2): a feasible tool to monitor immediate treatment response to endovascular therapy of peripheral arterial disease? Cardiovasc Intervent Radiol. 2021;44(4):633–41.

18. Terlouw LG, Moelker A, Abrahanssen J, Acosta S, Bakker OJ, Baumgartner L, Boyer L, Cortes O, van Dijk LJ, Durnan M, Geelkerken RH, Illuminati G, Jackson RW, Kolkman JJ, Lonn L, Mazzei MA, Nuzzo A, Pecoraro F, Raupach J, Verhagen H, Zech CJ, van Noord D, Bruno MJ. European guidelines on chronic mesenteric ischaemia - joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, Cardiovascular and Interventional Radiological Society of Europe, and Dutch Mesenteric Ischaemia Study group clinical guidelines on the diagnosis and treatment of patients with chronic mesenteric ischaemia. Eur J Gastroenterol Hepatol. 2020;32(4):371–95.

19. Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, Hamdan AD, Landry GJ, Yamaguchi DJ, Society for Vascular Surgery. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg. 2016;64(4):e1–21.

20. Schaefer PJ, Pfarr J, Trentmann J, Wulff AM, Langer C, Siggelkow M, Groß J, Knabe H, Schaefer FK. Comparison of noninvasive imaging modalities for stenosis grading in mesenteric arteries. Rofo. 2013;185(7):628–34.

21. Sacks D, McClenney TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–202.

22. Hall Barrientos P, Knight K, Black D, Vesey A, Rodtiti G. A pilot study investigating the use of 4D flow MRI for the assessment of splanchic flow in patients suspected of mesenteric ischaemia. Sci Rep. 2021;11(1):5914.

23. Augustin AM, Welsch S, Bley TA, Lopau K, Kickuth R. Color-coded summation images in the evaluation of renal artery stenosis before and after percutaneous transluminal angioplasty. BMC Med Imaging. 2021;21(12):21.

24. Manke C, Strotzer M, Seitz J, Lenhart M, Aebert H, Kasprzak P, Kaiser B, Feuerbach S. Ischämische Komplikationen bei Aortendissektion-Perkutan Behandlung mit Ballonfensterung und Stentimplantation [Ischemic complications in aortic dissection–percutaneous treatment with balloon fenestration and stent implantation]. Rofo. 1999;170(2):198–204.

25. Erden A, Yurdakul M, Cumhur T. Doppler waveforms of the normal and collateralized inferior mesenteric artery. AOR Am J Roentgenol. 1998;171(3):619–27.

26. Sugiyama M, Takehara Y, Kawate M, Ooishi N, Terada M, Isoda H, Sakahara H, Naganawa S, Johnson KM, Wieben O, Wakayama T, Nozaki A, Kaba sushiwa H. Optimal plane selection for measuring post-prandial blood flow increase within the superior mesenteric artery: analysis using 4D flow and computational fluid dynamics. Magn Reson Med Sci. 2020;19(4):366–74.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions